

**MATERIALS LICENSE**

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<b>Licensee</b> 1. Indiana University Health Bloomington Hospital  2. P.O. Box 1149 Radiology Department Bloomington, IN 47402		In accordance with application dated May 15, 2020,  3. License No.: 13-10408-02 is renewed in its entirety to read as follows:	4. Expiration Date: November 30, 2035  5. Docket No.: 030-01644 Reference No.:
6. Byproduct, source, and/or special nuclear material  A. Any byproduct material permitted by 10 CFR 35.100  B. Any byproduct material permitted by 10 CFR 35.200  C. Any byproduct material permitted by 10 CFR 35.300  D. Any byproduct material permitted by 10 CFR 31.11	7. Chemical and/or physical form  A. Any  B. Any  C. Any  D. Prepackaged Kits	8. Maximum amount that licensee may possess at any one time under this license  A. As Needed  B. As Needed  C. 1 curie total  D. 2 millicuries total	9. Authorized use  A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100.  B. For use in imaging and localization studies permitted by 10 CFR 35.200.  C. For any use permitted by 10 CFR 35.300.  D. For use in in-vitro studies.

**CONDITIONS**

10. A. Licensed material may be used or stored at the licensee's facilities located at 605-625 W Second St., Bloomington, Indiana, 47403.  
 B. Licensed material listed in Subitem Nos. 6.A. through 6.C. may be used at the licensee's facilities located at 500 Landmark Ave., Bloomington, Indiana, 47403.

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License No.: 13-10408-02

Docket or Reference No.:  
030-01644

Amendment No. 76

11. The Radiation Safety Officer (RSO) for this license is Patrick J. Byrne, DABR, CHP.

12. Licensed material shall only be used by, or under the supervision of:

A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.

B. The following individuals are authorized users for the material and medical uses as indicated:

Authorized User (M.D.,D.O.,etc.)Material and Use

Neal David Abdullah, M.D.

10 CFR 31.11, 10 CFR 35.100, 10 CFR 35.200

John Alexander, M.D.

10 CFR 31.11, 10 CFR 35.100, 10 CFR 35.200; 10 CFR 35.300 (limited to oral administration of sodium iodide I-131 in quantities of 33 millicuries or less).

Sean M. Flynn, M.D.

10 CFR 31.11, 10 CFR 35.100, 10 CFR 35.200; 10 CFR 35.300 (limited to oral administration of sodium iodide I-131 in quantities of 33 millicuries or less).

Douglas D. Geiger, M.D.

10 CFR 31.11, 10 CFR 35.100, 10 CFR 35.200

Jennifer Peterson Goldspiel, M.D.

10 CFR 35.100, 10 CFR 35.200

David Y. Lee, M.D.

10 CFR 31.11; 10 CFR 35.300 (limited to oral administration of sodium iodide I-131 in quantities of 33 millicuries or less and to the parenteral administration of unsealed byproduct material requiring a written directive).

Chris W. McGary, M.D.

10 CFR 31.11, 10 CFR 35.100, 10 CFR 35.200; 10 CFR 35.300 (limited to oral administration of sodium iodide I-131 in quantities of 33 millicuries or less).

Nicholas P. Miller, M.D.

10 CFR 35.100, 10 CFR 35.200; 10 CFR 35.300 (limited to oral administration of sodium iodide I-131).

Bruce N. Monson, M.D.

10 CFR 31.11, 10 CFR 35.100, 10 CFR 35.200; 10 CFR 35.300 (limited to oral administration of sodium iodide I-131 in quantities of 33 millicuries or less).

Jonathan A. Staser, M.D.

10 CFR 31.11, 10 CFR 35.100, 10 CFR 35.200; 10 CFR 35.300 (limited to oral administration of sodium iodide I-131 in quantities of 33 millicuries or less).

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License No.: 13-10408-02

Docket or Reference No.:  
030-01644

Amendment No. 76

Authorized User (M.D., D.O., etc.)

Todd A. Winkler, M.D.

George K. Wolfer, Jr., M.D.

Material and Use

10 CFR 31.11, 10 CFR 35.100, 10 CFR 35.200

10 CFR 31.11, 10 CFR 35.100, 10 CFR 35.200; 10 CFR 35.300 (limited to oral administration of sodium iodide I-131 in quantities of 33 millicuries or less)

13. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Application dated May 15, 2020 (ML20139A078)
  - B. Letter dated September 1, 2020 (ML20304A227)
  - C. Letter dated November 2, 2020 (ML20308A404)

The seal of the U.S. Nuclear Regulatory Commission is centered in the background. It features an eagle with wings spread, holding an olive branch and arrows. The eagle's chest is covered by a shield with vertical stripes. Above the eagle's head is a banner with the words "UNITED STATES OF AMERICA". Below the eagle are five stars. The words "U.S. NUCLEAR REGULATORY COMMISSION" are written in a circular path around the eagle.  
FOR THE U.S. NUCLEAR REGULATORY COMMISSIONDate: November 10, 2020

By: \_\_\_\_\_

Sara A. Forster  
Region III